COMMUNIQUÉS West-GlobeNewswire

AIT Therapeutics Announces Further Data From Its NO-NTM Abscessus Phase 2 Clinical Trial in Nontuberculous Mycobacteria (NTM) Patients
22/01/2018
Mycobacterium Abscessus Load Reduced by 65% 6-Minute Walk Improvement Maintained at Day 81 NEW YORK, Jan. 22, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused [...]
Rexahn Pharmaceuticals Announces Poster Presentation of RX-3117 Data in Metastatic Pancreatic Patients at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI) 2018 Annual Meeting
22/01/2018
Encouraging Progression Free Survival and Evidence of Tumor Shrinkage Observed in Patients with Metastatic Pancreatic Cancer Resistant to Gemcitabine who had Failed on Multiple Prior Treatments Rexahn is Progressing [...]
Athenex, Inc. Announces Proposed Offering of Common Stock
22/01/2018
BUFFALO, N.Y., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Athenex (Nasdaq: ATNX ), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer [...]
Myriad Applauds New Consensus Statement From International Expert Panel On Screening Recommendations for Hereditary Prostate Cancer
22/01/2018
SALT LAKE CITY, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN ), a leader in molecular diagnostics and personalized medicine, announced today that the company is applauding a new consensus [...]
Shire to Present Data on Short Bowel Syndrome With Intestinal Failure at the ASPEN 2018 Nutrition Science & Practice Conference
22/01/2018
Shire to Present Data on Short Bowel Syndrome With Intestinal Failure at the ASPEN 2018 Nutrition Science & Practice Conference Cambridge, Mass. - January 22, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG), the global [...]
Athenex Announces Encouraging Early Clinical Efficacy and Safety Data of Oraxol in Clinical Trial for the Treatment of Breast Cancer
22/01/2018
BUFFALO, N.Y., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Athenex (Nasdaq: ATNX ), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer [...]
Endonovo Announces First Commercial Sales for SofPulse Wearable Electroceutical for Post-Operative Pain and Edema
22/01/2018
Seeking Distribution Partners in Europe for CE-Marked Electroceutical™ Device for Promotion of Wound Healing, Reduction of Pain and Post-Operative Edema LOS ANGELES, CA, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Endonovo [...]
IRADIMED CORPORATION Announces 2018 Annual and First Quarter Financial Guidance
22/01/2018
Announces Preliminary Full Year and Fourth Quarter 2017 Revenue Announces Fourth Quarter 2017 Financial Results Conference Call Date WINTER SPRINGS, Fla., Jan. 22, 2018 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: [...]
Le conseil d’administration de la Société canadienne du sang a un nouveau président
22/01/2018
OTTAWA, 22 janv. 2018 (GLOBE NEWSWIRE) -- La Société canadienne du sang est heureuse d’annoncer la nomination de M. Mel Cappe à la présidence de son conseil d’administration. La nomination entre en vigueur immédiatement [...]
New board chair for Canadian Blood Services
22/01/2018
OTTAWA, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Canadian Blood Services is pleased to announce the appointment of Mel Cappe as chair of the board of directors, effective immediately. With over 30 years of varied experience in [...]
Neuralstem to Participate at Cell and Gene Therapy World
22/01/2018
GERMANTOWN, Md., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq: CUR ), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced Karl Johe, Ph.D, Chief [...]
Athenex Announces Encouraging Results of the First Cohort of Phase I Clinical Trial of Oraxol and CYRAMZA® (Ramucirumab) Combination Treatment in Gastric Cancer
22/01/2018
BUFFALO, N.Y., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq: ATNX ), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]
Elysium Health, Inc. Challenge of ChromaDex Licensed Patent Denied by Patent Trial and Appeal Board (PTAB)
22/01/2018
IRVINE, Calif., Jan. 22, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ: CDXC ), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that the Patent Trial and [...]
Novo Nordisk A/S - Share repurchase programme
22/01/2018
Bagsværd, Denmark, 22 January 2018 - On 1 November 2017, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April [...]
Astellas and Vical Announce Top-Line Results for Phase 3 Trial of Cytomegalovirus Vaccine ASP0113 in Hematopoietic Stem Cell Transplant Recipients
22/01/2018
TOKYO and SAN DIEGO, Jan. 22, 2018 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE: 4503 ) (President and CEO: Yoshihiko Hatanaka, “Astellas”) and Vical Incorporated (NASDAQ: VICL ) announced today that ASP0113, an [...]
Solon Eiendom ASA : Primary insider notification
22/01/2018
SOLON EIENDOM ASA STOCK EXCHANGE ANNOUNCEMENT Solon Eiendom ASA - Primary insider notification (Oslo, Norway, January 19, 2018) Solon Eiendom ASA Board Member Tore Aksel Voldberg (through his wholly owned company Skøien [...]
Genmab Announces Novartis’ Intention to Transition Arzerra® (ofatumumab) from Commercial Availability to Limited Availability via Compassionate Use Programs for the Treatment of CLL in Non-US Markets
22/01/2018
Company Announcement Novartis intends to transition the commercial availability of Arzerra to limited availability via compassionate use programs for treatment of CLL in non-US markets. Novartis will continue to market [...]
NANOBIOTIX presents first promising data from Phase I/II Liver Cancers trial of NBTXR3 at the American Society Of Clinical Oncology Gastrointestinal Annual Meeting
22/01/2018
NANOBIOTIX PRESENTS FIRST PROMISING DATA FROM PHASE I/II LIVER CANCERS TRIAL OF NBTXR3 AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY GASTROINTESTINAL ANNUAL MEETING Very good safety profile with no AEs and SAEs related [...]
NANOBIOTIX présente de premières données prometteuses dans l'essai de phase I/II avec NBTXR3 dans les cancers du foie à l'ASCO GI
22/01/2018
Nanobiotix présente de premières données prometteuses dans l'essai de phase I/II avec NBTXR3 dans les cancers du foie à l' American Society of Clinical Oncology Gastrointestinal Annual Meeting (ASCO GI) Très bon profil [...]

Pages